Stimulant therapy

ApprovedSmall molecule

Otsuka

Stimulant therapy is one of 13 small molecule programs targeting Executive Function. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Executive FunctionActive, not recruiting

Executive FunctionApproved

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Executive Function

#DrugCompanyPhaseTrials

Ritalin

Novartis

Approved

2 2

Vyvanse

Takeda

Approved

1 3

Azilect

Teva

Approved

1 4

Intuniv

PPromius Pharma, LLC

Approved

1 5

Strattera

MMap77

Approved

1 6

Methylphenidate Hydrochloride

Takeda

Approved

1 7

Tasmar

BBausch Health Americas, Inc.

SPD489

1 9

Stimulant therapy

Otsuka

Approved

1 10

MYDAYIS

MMayo Clinic

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Executive Function1 trial

Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD

Completed·JJPM van Stralen Medicine Professional·Phase 4·NCT01985581·50 enrolled

Safety and Efficacy1 trial

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

Completed· Otsuka logo

Otsuka·Phase 2·NCT01074294·740 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Stimulant therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Stimulant therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Stimulant therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Otsuka company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Otsuka

Stimulant therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Executive Function1 trial

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News